MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
AMRN

AMRN

Amarin Corporation plc

$14.26
-0.12
 (-0.8%)
Exchange:  NASDAQ
Market Cap:  294.936M
Shares Outstanding:  112500
Delayed data
Calculate AMRN Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – General
   
CEO:  Aaron D. Berg
Full Time Employees:  80
Address: 
One Central Plaza
Dublin
DU
D02 K7K5
IE
Website:  https://www.amarincorp.com
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company’s flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa’s active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/04/29 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue306,911228,614213,646
Gross Profit165,54181,382120,868
EBITDA-50,697-74,180-33,013
Operating Income-56,616-91,797-13,941
Net Income-59,112-82,183-38,798

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets831,684685,349670,774.999
Total Liabilities279,587199,173211,494
Total Stockholders Equity552,097486,176459,281
Total Debt8,7377,72312,160
Cash and Cash Equivalents199,252121,038134,861

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow6,880-31,0206,743.722
Capital Expenditure-53300
Free Cash Flow6,347-31,0206,743.720
Net Income-59,112-82,1830
Net Change in Cash-18,412-78,43913,523

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2029Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)224,551.532Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)243,648.469Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)234,100Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-43,488.667Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-40,080.067Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-41,784.367Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)3,733.403Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)4,151.292Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)3,942.348Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)151,827.986Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)164,740.165Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)158,284.075Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.190Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0.200Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.180Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)1Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
228.71M  ?P/S
 (TTM)
: 
1.57
?Net Income
 (TTM)
: 
-82217581.68  ?P/E
 (TTM)
: 
-9.86
?Enterprise Value
 (TTM)
: 
153.117M  ?EV/FCF
 (TTM)
: 
3.11
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-5.99%  ?ROIC
 (TTM)
: 
-7.25%
?Net Debt
 (TTM)
: 
-286797000  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
0.66  ?Current Ratio
 (TTM)
: 
3.67

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
101.86Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about AMRN valuation

Is Amarin Corporation plc (AMRN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Amarin Corporation plc (AMRN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is AMRN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AMRN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is AMRN’s P/E ratio?

You can see AMRN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for AMRN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is AMRN a good long-term investment?

Whether AMRN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

AMRN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.8
MARKETSnap

Trading Metrics:

Open: 14.41   Previous Close: 14.38
Day Low: 14.13   Day High: 14.43
Year Low: 12.96   Year High: 20.9
Price Avg 50: 14.68   Price Avg 200: 14.83
Volume: 8130   Average Volume: 74283

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
29-07-2026 18:13
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
29-07-2026 13:21
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
29-04-2026 16:42
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read